Compare CFFN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | ABUS |
|---|---|---|
| Founded | 1893 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2010 | 2008 |
| Metric | CFFN | ABUS |
|---|---|---|
| Price | $8.80 | $5.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.25 | $5.00 |
| AVG Volume (30 Days) | 711.2K | ★ 4.3M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ 79.31 | 55.26 |
| EPS | 0.51 | ★ 0.84 |
| Revenue | ★ $16,300,000.00 | $14,083,000.00 |
| Revenue This Year | $20.16 | N/A |
| Revenue Next Year | $6.62 | $239.71 |
| P/E Ratio | $17.25 | ★ $6.17 |
| Revenue Growth | 6.54 | ★ 128.21 |
| 52 Week Low | $5.97 | $3.50 |
| 52 Week High | $9.26 | $5.45 |
| Indicator | CFFN | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 53.34 | 64.76 |
| Support Level | $8.43 | $4.34 |
| Resistance Level | $8.84 | $5.42 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 71.29 | 61.97 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.